Resistencia a la terapia antirretroviral en pacientes infectados con el virus VIH-1 en Chile 2002-2005

Background: Resistance limits the effectiveness of anti-retroviral therapy. In Chile, there is free access to highly active anti-retroviral therapy since 2001, but there is no information about the frequency of mutations associated to drug resistance. Aim: To determine the most common mutations asso...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Afani S,Alejandro, Orellana R,Laura, Duarte J,Paula, Acevedo M,William, Morales B,Ornar, Wolff R,Marcelo, Vásquez,Patricia, Beltrán,Carlos
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2007
Materias:	Anti-retroviral agents HIV-1 Nucleosides
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007001000002
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872007001000002
record_format	dspace
spelling	oai:scielo:S0034-988720070010000022007-12-20Resistencia a la terapia antirretroviral en pacientes infectados con el virus VIH-1 en Chile 2002-2005Afani S,AlejandroOrellana R,LauraDuarte J,PaulaAcevedo M,WilliamMorales B,OrnarWolff R,MarceloVásquez,PatriciaBeltrán,Carlos Anti-retroviral agents HIV-1 Nucleosides Background: Resistance limits the effectiveness of anti-retroviral therapy. In Chile, there is free access to highly active anti-retroviral therapy since 2001, but there is no information about the frequency of mutations associated to drug resistance. Aim: To determine the most common mutations associated to anti-retroviral drug resistance in Chile. Materials and Methods: Retrospective study of 710 genotype analysis coming from 568 patients aged 22 to 70 years (85% males) with virological failure. The analysis was performed using a commercially available sequencing kit (Trugene HIV-1 genotypic assay from Bayer S.A). Results: Mean CD4+ cell count and viral load were 154 cells/fil and 228784 RNA copies/ml, respectively. The frequency of resistance to nucleoside RT inhibitors (NRTI), non nucleoside RT inhibitors (NNRTI) and protease inhibitors (PI) was 71 %, 62% and 22%, respectively. The most common mutations found were T215Y (46%), L10F (44%), Ml84V (3896), K103N (35%) and M41L (32%). Fifty five percent of mutations corresponded to the TAM (thymidine analogue mutations) group. Multiresistance was 47% to NNRTI, 7% to NRTI, 4% to PI and 0.7% to all groups. During the four years of the study, there was a significant increase in NNRTI resistance. Conclusions: These data provides important information about the epidemiology of drug resistance mutations and should help to design newHAARTstrategiesinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.135 n.10 20072007-10-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007001000002es10.4067/S0034-98872007001000002
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Anti-retroviral agents HIV-1 Nucleosides
spellingShingle	Anti-retroviral agents HIV-1 Nucleosides Afani S,Alejandro Orellana R,Laura Duarte J,Paula Acevedo M,William Morales B,Ornar Wolff R,Marcelo Vásquez,Patricia Beltrán,Carlos Resistencia a la terapia antirretroviral en pacientes infectados con el virus VIH-1 en Chile 2002-2005
description	Background: Resistance limits the effectiveness of anti-retroviral therapy. In Chile, there is free access to highly active anti-retroviral therapy since 2001, but there is no information about the frequency of mutations associated to drug resistance. Aim: To determine the most common mutations associated to anti-retroviral drug resistance in Chile. Materials and Methods: Retrospective study of 710 genotype analysis coming from 568 patients aged 22 to 70 years (85% males) with virological failure. The analysis was performed using a commercially available sequencing kit (Trugene HIV-1 genotypic assay from Bayer S.A). Results: Mean CD4+ cell count and viral load were 154 cells/fil and 228784 RNA copies/ml, respectively. The frequency of resistance to nucleoside RT inhibitors (NRTI), non nucleoside RT inhibitors (NNRTI) and protease inhibitors (PI) was 71 %, 62% and 22%, respectively. The most common mutations found were T215Y (46%), L10F (44%), Ml84V (3896), K103N (35%) and M41L (32%). Fifty five percent of mutations corresponded to the TAM (thymidine analogue mutations) group. Multiresistance was 47% to NNRTI, 7% to NRTI, 4% to PI and 0.7% to all groups. During the four years of the study, there was a significant increase in NNRTI resistance. Conclusions: These data provides important information about the epidemiology of drug resistance mutations and should help to design newHAARTstrategies
author	Afani S,Alejandro Orellana R,Laura Duarte J,Paula Acevedo M,William Morales B,Ornar Wolff R,Marcelo Vásquez,Patricia Beltrán,Carlos
author_facet	Afani S,Alejandro Orellana R,Laura Duarte J,Paula Acevedo M,William Morales B,Ornar Wolff R,Marcelo Vásquez,Patricia Beltrán,Carlos
author_sort	Afani S,Alejandro
title	Resistencia a la terapia antirretroviral en pacientes infectados con el virus VIH-1 en Chile 2002-2005
title_short	Resistencia a la terapia antirretroviral en pacientes infectados con el virus VIH-1 en Chile 2002-2005
title_full	Resistencia a la terapia antirretroviral en pacientes infectados con el virus VIH-1 en Chile 2002-2005
title_fullStr	Resistencia a la terapia antirretroviral en pacientes infectados con el virus VIH-1 en Chile 2002-2005
title_full_unstemmed	Resistencia a la terapia antirretroviral en pacientes infectados con el virus VIH-1 en Chile 2002-2005
title_sort	resistencia a la terapia antirretroviral en pacientes infectados con el virus vih-1 en chile 2002-2005
publisher	Sociedad Médica de Santiago
publishDate	2007
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007001000002
work_keys_str_mv	AT afanisalejandro resistenciaalaterapiaantirretroviralenpacientesinfectadosconelvirusvih1enchile20022005 AT orellanarlaura resistenciaalaterapiaantirretroviralenpacientesinfectadosconelvirusvih1enchile20022005 AT duartejpaula resistenciaalaterapiaantirretroviralenpacientesinfectadosconelvirusvih1enchile20022005 AT acevedomwilliam resistenciaalaterapiaantirretroviralenpacientesinfectadosconelvirusvih1enchile20022005 AT moralesbornar resistenciaalaterapiaantirretroviralenpacientesinfectadosconelvirusvih1enchile20022005 AT wolffrmarcelo resistenciaalaterapiaantirretroviralenpacientesinfectadosconelvirusvih1enchile20022005 AT vasquezpatricia resistenciaalaterapiaantirretroviralenpacientesinfectadosconelvirusvih1enchile20022005 AT beltrancarlos resistenciaalaterapiaantirretroviralenpacientesinfectadosconelvirusvih1enchile20022005
_version_	1718436342585622528

Resistencia a la terapia antirretroviral en pacientes infectados con el virus VIH-1 en Chile 2002-2005

Ejemplares similares